الفهرس Only 14 pages are availabe for public view
 |  | from | 124 |  |  |
| | | from | 124 | | |
Abstract
BACKGROUND: DNA methylation is one of the most important epigenetic mechanisms, which denotes the addition of a methyl group to DNA. Aberrant promoter demethylation is usually associated with overexpression of genes that might participate in pathogenesis of many diseases AIM OF THE WORK: to evaluate serum ALX4, SEPT9, CDH4 and CDKN2B/P15 and their candidacy as novel noninvasive markers, in CRC among Egyptian patients. METHODS: A whole blood sample (10cc) will be collected in an EDTA-containing vacutainer tube and stored at 4C for a maximum of 24 hours. Samples will be delivered within this period to the molecular biochemistry lab for removal of the Buffy coat, DNA extraction and analysis. The molecular biologist will assess all samples in a blinded fashion. RESULTS: ALX4 shows the highest sensitivity (97.6%) and specificity (99.3%) with cut-off of 0.315 æg/L Followed by CDKN2B/P15 (sensitivity=96.1% and specificity=97.8%) with cut-off of 0.412 æg/L and SEPT9 (sensitivity=87.4% and specificity=98.5%) with cut-off of 0.461 æg/L while CDH4 shows the least sensitivity=75.6% and specificity=70.1% with cut-off of 0.330 æg/L. CONCLUSON: ALX4, SEPT9, CDH4 and CDKN2B/P15 can be useful in high prediction of colorectal carcinoma with high sensitivity and specificity